KLEPTOSE® HPB LB PARENTERAL
KLEPTOSE®
®Registered Trademark(s) of Roquette Frères
- Molecular encapsulation
- Improve injectable API solubility and/or stability
Medium molecular substitution (MS) = 0.50 - 0.71
Applications
- Injectable
- Rx Injectable
- Specialty APIs
Functional properties
- APIs
- Encapsulating agent
- Excipients
- Solubilizer
- Stabilizer
Physical and chemical properties
- CEP & DMF available
Documents
Product Specification Sheet
Name
Region
Size
Download
KLEPTOSE® HPB-LB Parenteral Grade
488,73 Ko
Region :
488,73 Ko
Safety Data Sheet
Name
Region
Language
Size
Download
KLEPTOSE® HPB-LB Parenteral Grade
Asia, CN
EN
316,86 Ko
Region : Asia, CN
EN
316,86 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Europe, DE
EN
375,97 Ko
Region : Europe, DE
EN
375,97 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Europe, FR
EN
373,41 Ko
Region : Europe, FR
EN
373,41 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Americas, Asia, Oceania, Africa
EN
263,17 Ko
Region : Americas, Asia, Oceania, Africa
EN
263,17 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Americas, US
EN
322,62 Ko
Region : Americas, US
EN
322,62 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Asia, CN
ZH
599,05 Ko
Region : Asia, CN
ZH
599,05 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Europe, DE
DE
387,38 Ko
Region : Europe, DE
DE
387,38 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Europe, FR
FR
483,07 Ko
Region : Europe, FR
FR
483,07 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Americas, Asia, Oceania, Africa
ES
274,30 Ko
Region : Americas, Asia, Oceania, Africa
ES
274,30 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Americas, Asia, Oceania, Africa
PT
279,04 Ko
Region : Americas, Asia, Oceania, Africa
PT
279,04 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Americas, Asia, Oceania, Africa
RU
403,09 Ko
Region : Americas, Asia, Oceania, Africa
RU
403,09 Ko
KLEPTOSE® HPB-LB Parenteral Grade
Europe, IT
IT
472,37 Ko
Region : Europe, IT
IT
472,37 Ko
Get in touch with our Technical Experts
Please feel free to contact our technical experts for support during the development process.
Technical data
| Synonyms | HYDROXYPROPYLBETADEX |
|---|---|
| CAS number | 128446-35-5 |
| Physical form or apperance | White or almost white amorphous powder. The statistical hydroxypropylation of beta-cyclodextrin creates a multitude of molecules, differing by the position of the hydroxypropyl groups. Consequently, the product is not able to crystallize and remains in the amorphous state. |
| Application | KLEPTOSE® HPB-LB parenteral hydroxypropyl β-cyclodextrin. It is a pyrogen-free solution that improves drug solubility and stability against light or oxidation by molecular encapsulation. It also reduces irritation at injection site. KLEPTOSE® HPB-LB is a multi-compendial product that complies with European and U.S. Pharmacopeia, and has standards that not only comply with but are even higher than Chinese Pharmacopeia. |
| Morphology |
|
| Water sorption isotherm at 20°C |
|
| Chemical Structure |
|
| Glass Transition Temperature vs. Water Content |
|
| Viscosity in water at 2°C |
|
| Minimum molecular weight | 1338 g/mol |
| Maximum molecular weight | 1424 g/mol |
| Maximal Water content (LOD) | 10.00 |
| Minimum Molar substitution range | 0.50 |
| Maximum Molar substitution range | 0.71 |
| Solubility | Highly soluble in water. At high concentration, the wetting and dissolution time of the powder is delayed due to its low density and increased viscosity Soluble in ethanol. Freely soluble in propylen glycol. |
| Glass Transition Temperature of the Cryo-Concentrated Phase | -11.10 |